Article
02 Apr 2025
Prosecution Disclaimer In A Member Of A Patent Family Over The Prosecution History Of Another Member Of The Family
AUTHORS CONTENT
Article
13 Mar 2025
WEBINAR: Listing Medical Devices In The Orange Book After Teva v. Amneal (Video)
Article
17 Jan 2025
The CAFC Backs The FTC View On Listing Device Patents In The Orange Book
Article
19 Nov 2024
WEBINAR: Using The Amgen-Sanofi Methodology To Identify The Historic Treatment Of Patent Eligibility Issues: Today's 35 U.S.C. 101 Issues (Video)
Article
04 Oct 2024
Myrbetriq® Patent Invalidated On Grounds Not Asserted By Any Party Violating Party Presentation Principle
Article
30 Aug 2024
Finally, An ODP Decision In Favor Of The Patentee
Article
23 Feb 2024
Written Description Of A Numerical Range
Article
31 Jan 2024
When Does A Drug Label Induce Infringement Under 35 U.S.C. § 271(e)(2) Of A Patent Not Claiming An Indication Or Method Of Use?
Article
15 Jan 2024
USPTO Releases Examiner Guidance For The Amgen Enablement Decision
Article
27 Dec 2023
In Patent Eligibility It's The Claim That Is The Name Of The Game*
Article
29 Nov 2023
Generics Beat The Tax Man
Article
22 Nov 2023
Sisvel – PTAB Guidance On A Proposed Amendment In An IPR Is Not Binding On The PTAB
Article
15 Nov 2023
FTC Alleges Misuse Of Orange Book Listings: Puts10 Pharma Companies On Notice
Article
23 Oct 2023
FDA Announces Formation Of A New Digital Health Advisory Committee
Article
26 Sep 2023
The Federal Circuit's First Enablement Decision Since Amgen
Article
18 Sep 2023
In Re Cellect – ODP Defense Does Not Impact The Expiration Date Of A Patent With Both PTA And PTE In The Absence Of A Terminal Disclaimer
Article
08 Aug 2023
American Axle Part 2 – Not An Abstract Idea
Article
28 Jul 2023
USPTO Announces Revised Director Review Process
Article
13 Jul 2023
The Federal Circuit Takes Design Patent Obviousness En Banc
Article
10 Jul 2023
Lessons From Amgen v. Sanofi